View Item 

Show simple item record

An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV‐based vaginal rings
dc.contributor.authorMacQueen, Kathleen M
dc.contributor.authorTolley, Elizabeth E
dc.contributor.authorOwen, Derek H
dc.contributor.authorAmico, K Rivet
dc.contributor.authorMorrow, Kathleen M
dc.contributor.authorMoench, Thomas
dc.contributor.authorFriend, David R
dc.contributor.authorFriedland, Barbara
dc.date.accessioned2017-10-05T18:16:43Z
dc.date.available2017-10-05T18:16:43Z
dc.date.issued2014-09
dc.identifier.citationMacQueen, Kathleen M; Tolley, Elizabeth E; Owen, Derek H; Amico, K Rivet; Morrow, Kathleen M; Moench, Thomas; Friend, David R; Friedland, Barbara (2014). "An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV‐based vaginal rings." Journal of the International AIDS Society 17: n/a-n/a.
dc.identifier.issn1758-2652
dc.identifier.issn1758-2652
dc.identifier.urihttps://hdl.handle.net/2027.42/138229
dc.publisherInternational AIDS Society
dc.publisherWiley Periodicals, Inc.
dc.subject.othermeasurement
dc.subject.otherHIV prevention
dc.subject.otherclinical trial research
dc.subject.otheradherence
dc.subject.otheracceptability
dc.subject.othervaginal ring
dc.titleAn interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV‐based vaginal rings
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMicrobiology and Immunology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, USA
dc.contributor.affiliationotherContraceptive Technology Institute, FHI 360, Durham, NC, USA
dc.contributor.affiliationotherSocial and Behavioral Health Sciences, FHI 360, Durham, NC, USA
dc.contributor.affiliationotherPopulation Council, New York, NY, USA
dc.contributor.affiliationotherProduct Development, CONRAD, Arlington, VA, USA
dc.contributor.affiliationotherThe Johns Hopkins University, Baltimore, MD, USA
dc.contributor.affiliationotherReprotect Inc, Baltimore, MD, USA
dc.contributor.affiliationotherDepartment of Psychiatry & Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA
dc.contributor.affiliationotherCenters for Behavioral & Preventive Medicine, The Miriam Hospital, Providence, RI, USA
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138229/1/jia29158.pdf
dc.identifier.doi10.7448/IAS.17.3.19158
dc.identifier.sourceJournal of the International AIDS Society
dc.identifier.citedreferenceSafren SA, Otto MW, Worth JL, Salomon E, Johnson W, Mayer K, et al. Two strategies to increase adherence to HIV antiretroviral medication: life‐steps and medication monitoring. Behav Res Ther. 2001; 39 ( 10 ): 1151 – 62.
dc.identifier.citedreferenceMack N, Robinson ET, MacQueen KM, Moffett J, Johnson LM. The exploitation of “Exploitation” in the tenofovir prep trial in Cameroon: lessons learned from media coverage of an HIV prevention trial. J Empir Res Hum Res Ethics. 2010; 5 ( 2 ): 3 – 19.
dc.identifier.citedreferenceSaethre E, Stadler J. Malicious whites, greedy women, and virtuous volunteers: negotiating social relations through clinical trial narratives in South Africa. Med Anthropol Q. 2013; 27 ( 1 ): 103 – 20.
dc.identifier.citedreferenceWoodsong C, Macqueen K, Namey E, Sahay S, Morar N, Mlingo M, et al. Women’s autonomy and informed consent in microbicides clinical trials. J Empir Res Hum Res Ethics. 2006; 1 ( 3 ): 11 – 26.
dc.identifier.citedreferenceMngadi KT, Maarschalk S, Grobler AC, Mansoor LE, Frohlich JA, Madlala B, et al. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav. 2014; 18 ( 5 ): 849 – 54.
dc.identifier.citedreferenceSuccop SM, MacQueen KM, van Loggerenberg F, Majola N, Abdool Karim Q, Abdool Karim SS. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. AIDS Care. 2014.
dc.identifier.citedreferenceMontgomery ET, van der Straten A, Chidanyika A, Chipato T, Jaffar S, Padian N. The importance of male partner involvement for women’s acceptability and adherence to female‐initiated HIV prevention methods in Zimbabwe. AIDS Behav. 2011; 15 ( 5 ): 959 – 69.
dc.identifier.citedreferenceWare NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, et al. What’s love got to do with it? Explaining adherence to oral antiretroviral preexposure prophylaxis for HIV‐serodiscordant couples. J Acquir Immune Defic Syndr. 2012; 59 ( 5 ): 463 – 8.
dc.identifier.citedreferenceMontgomery ET, van der Straten A, Cheng H, Wegner L, Masenga G, von Mollendorf C, et al. Vaginal ring adherence in sub‐Saharan Africa: expulsion, removal, and perfect use. AIDS Behav. 2012; 16 ( 7 ): 1787 – 98.
dc.identifier.citedreferenceNel A, Kamupira M, Woodsong C, van der Straten A, Montgomery E, van Niekerk N, et al., editors. Safety, acceptability and pharmacokinetic assessment (adherence) of monthly dapivirine vaginal rings (Ring‐004) for HIV prevention. CROI; 2012 Mar 3–8; Seattle, Washington, DC: International Partnership for Microbicides; 2012.
dc.identifier.citedreferencevan der Straten A, Montgomery ET, Hartmann M, Minnis A. Methodological lessons from clinical trials and the future of microbicide research. Curr HIV/AIDS Rep. 2013; 10 ( 1 ): 89 – 102.
dc.identifier.citedreferenceTolley EE, Harrison PF, Goetghebeur E, Morrow K, Pool R, Taylor D, et al. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav. 2010; 14 ( 5 ): 1124 – 36.
dc.identifier.citedreferenceKiser PF, Johnson TJ, Clark JT. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev. 2012; 14 ( 1 ): 62 – 77.
dc.identifier.citedreferenceFenton KA, Johnson AM, McManus S, Erens B. Measuring sexual behaviour: methodological challenges in survey research. Sex Transm Infect. 2001; 77 ( 2 ): 84 – 92.
dc.identifier.citedreferenceCatania JA, Binson D, Van Der Straten A, Stone V. Methodological research on sexual behavior in the AIDS era. Ann Rev Sex Res. 1995; 6 ( 1 ): 77 – 125.
dc.identifier.citedreferenceMuchomba FM, Gearing RE, Simoni JM, El‐Bassel N. State of science of adherence in pre‐exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr. 2012; 61 ( 4 ): 490 – 8.
dc.identifier.citedreferencePool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M, et al. A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme. PLoS One. 2010; 5 ( 7 ): 11600.
dc.identifier.citedreferenceAmico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013; 17 ( 6 ): 2143 – 55.
dc.identifier.citedreferenceAmico KR, McMahan V, Goicochea P, Vargas L, Marcus JL, Grant RM, et al. Supporting study product use and accuracy in self‐report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav. 2012; 16 ( 5 ): 1243 – 59.
dc.identifier.citedreferenceMansoor LE, Karim QA, Werner L, Madlala B, Ngcobo N, Cornman DH, et al. Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial. AIDS Behav. 2014; 18: 841 – 8.
dc.identifier.citedreferencePsaros C, Haberer JE, Katabira E, Ronald A, Tumwesigye E, Campbell JD, et al. An intervention to support HIV pre‐exposure prophylaxis (PrEP) adherence in HIV serodiscordant couples in Uganda. J Acquir Immune Defic Syndr. 2014; 66: 522 – 9.
dc.identifier.citedreferenceHolstad MM, Foster V, Diiorio C, McCarty F, Teplinskiy I. An examination of the psychometric properties of the Antiretroviral General Adherence Scale (AGAS) in two samples of HIV‐infected individuals. J Assoc Nurses AIDS Care. 2010; 21 ( 2 ): 162 – 72.
dc.identifier.citedreferenceRubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta‐analysis. Br J Gen Pract. 2005; 55 ( 513 ): 305 – 12.
dc.identifier.citedreferenceJoint United Nations Programme on HIV/AIDS (UNAIDS), AVAC. Good participatory practice guidelines for biomedical HIV prevention trials. 2nd ed. Geneva, Switzerland: UNAIDS; 2011.
dc.identifier.citedreferenceParticipants in the Conference on Ethical Aspects of Research in Developing Countries. Ethics. Fair benefits for research in developing countries. Science. 2002; 298 ( 5601 ): 2133 – 4.
dc.identifier.citedreferenceRennie S, Sugarman J. Developing ethics guidance for HIV prevention research: the HIV Prevention Trials Network approach. J Med Ethics. 2010; 36 ( 12 ): 810 – 5.
dc.identifier.citedreferenceDewing S, Mathews C, Schaay N, Cloete A, Louw J, Simbayi L. Behaviour change counselling for ARV adherence support within primary health care facilities in the Western Cape, South Africa. AIDS Behav. 2012; 16 ( 5 ): 1286 – 94.
dc.identifier.citedreferenceMorisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self‐reported measure of medication adherence. Med Care. 1986; 24 ( 1 ): 67 – 74.
dc.identifier.citedreferenceJohnson MO, Neilands TB, Dilworth SE, Morin SF, Remien RH, Chesney MA. The role of self‐efficacy in HIV treatment adherence: validation of the HIV Treatment Adherence Self‐Efficacy Scale (HIV‐ASES). J Behav Med. 2007; 30 ( 5 ): 359 – 70.
dc.identifier.citedreferenceDeVellis RF. Scale development theory and applications. 2nd ed. Thousand Oaks, CA: Sage; 2003.
dc.identifier.citedreferenceMahoney CA, Thombs DL, Howe CZ. The art and science of scale development in health education research. Health Educ Res. 1995; 10 ( 1 ): 1 – 10.
dc.identifier.citedreferenceGamst G, Meyers L, Guarino AJ, Burke HM. Scale development and validation. In: Guest G, Namey E, editors. Public health research methods [Internet]. Thousand Oaks, CA: Sage; 2015. p. 379 – 409.
dc.identifier.citedreferenceLiu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001; 134 ( 10 ): 968 – 77.
dc.identifier.citedreferenceHaberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013; 10 ( 9 ): 1001511.
dc.identifier.citedreferenceGengiah TN, Upfold M, Naidoo A, Mansoor LE, Feldblum PJ, Abdool Karim Q, et al. Monitoring microbicide gel use with real‐time notification of the container’s opening events: results of the CAPRISA Wisebag study. AIDS Behav. 2014; 18: 833 – 40.
dc.identifier.citedreferenceMorey TE, Wasdo S, Wishin J, Quinn B, van der Straten A, Booth M, et al. Feasibility of a breath test for monitoring adherence to vaginal administration of antiretroviral microbicide gels. J Clin Pharmacol. 2012; 53: 101 – 11.
dc.identifier.citedreferenceAbdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329 ( 5996 ): 1168 – 74.
dc.identifier.citedreferenceGrant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363 ( 27 ): 2587 – 99.
dc.identifier.citedreferenceThigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367 ( 5 ): 423 – 34.
dc.identifier.citedreferenceChoopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet. 2013; 381 ( 9883 ): 2083 – 90.
dc.identifier.citedreferenceBaeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367 ( 5 ): 399 – 410.
dc.identifier.citedreferencevan der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre‐exposure prophylaxis trials for HIV prevention. AIDS. 2012; 26 ( 7 ): F13 – 9.
dc.identifier.citedreferenceVan Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367 ( 5 ): 411 – 22.
dc.identifier.citedreferenceInternational Partnership for Microbicides. Two phase III sister studies of a microbicide ring to prevent HIV: the Ring Study & ASPIRE. International Partnership for Microbicides [cited 2014 Jun 28]; Available from: http://www.ipmglobal.org/node/668.
dc.identifier.citedreferenceMacqueen KM, Alleman P. International perspectives on the collection, storage, and testing of human biospecimens in HIV research. Ethics Hum Res. 2008; 30 ( 4 ): 9 – 14.
dc.identifier.citedreferencevan der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women’s experiences with oral and vaginal pre‐exposure prophylaxis: the VOICE‐C qualitative study in Johannesburg, South Africa. PLoS One. 2014; 9 ( 2 ): e89118.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jia29158.pdf
Size:
357.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.